Akshaya Kambhatla, MD
Endocrinology, Diabetes & Metabolism · Jacksonville, FLNPI 1427431667
Payments from drug & device makers
Across 340 payments — averaging $21.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$856
- Insulet Corporation$756
- Abbott$646
- Lilly USA, LLC$643
- Corcept Therapeutics$519
- Medtronic$483
- plus $3K from 28 others
What the payments were for
- Food & beverage$7,142100%
- Education$260%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 38 | $856 |
| Insulet Corporation | 52 | $756 |
| Abbott | 31 | $646 |
| Lilly USA, LLC | 33 | $643 |
| Corcept Therapeutics | 19 | $519 |
| Medtronic | 19 | $483 |
| Boehringer Ingelheim | 20 | $444 |
| Amgen(2 entities) | 22 | $416 |
| Dexcom, Inc. | 17 | $331 |
| Bayer | 12 | $204 |
| Neurocrine Biosciences, Inc. | 4 | $201 |
| AstraZeneca | 6 | $186 |
| BETA Bionics, Inc. | 7 | $152 |
| Tandem Diabetes Care, Inc. | 8 | $148 |
| Cequr Corporation | 2 | $142 |
| Sanofi-aventis U.S. LLC | 5 | $117 |
| Xeris Pharmaceuticals, Inc. | 6 | $117 |
| Radius Health, Inc. | 4 | $107 |
| Novartis | 5 | $103 |
| Sequel Med Tech, LLC | 4 | $78 |
| Kvk-tech, Inc. | 1 | $58 |
| Rhythm Pharmaceuticals, Inc. | 2 | $57 |
| Amneal Pharmaceuticals LLC | 3 | $53 |
| Astellas Pharma US Inc | 3 | $51 |
| Kyowa Kirin, Inc. | 3 | $51 |
| Ascendis Pharma Endocrinology Inc | 3 | $50 |
| IBSA Pharma Inc. | 3 | $49 |
| Globus Medical | 2 | $36 |
| Halozyme Inc | 1 | $22 |
| Mannkind Corporation | 1 | $21 |
| Chiesi USA, Inc. | 1 | $21 |
| Ionis Pharmaceuticals, Inc. | 1 | $21 |
| Recordati_rare_diseases_inc. | 1 | $17 |
| AbbVie | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$260
- MINIMED 780G$160
- RYBELSUS$135
- CRENESSITY$129
- Korlym$125
- CeQur Simplicity$124
- JARDIANCE$123
- TEPEZZA$114
How this compares
$7,168 in reported general payments places this provider in the 60th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 358 | $597,810 |
| JardianceEmpagliflozin | 251 | $335,229 |
| MounjaroTirzepatide | 228 | $322,195 |
| TrulicityDulaglutide | 79 | $131,451 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 90 | $104,946 |
| FarxigaDapagliflozin Propanediol | 93 | $93,537 |
| TradjentaLinagliptin | 86 | $85,452 |
| JanuviaSitagliptin Phosphate | 57 | $79,683 |
| RybelsusSemaglutide | 36 | $61,630 |
| Tresiba Flextouch U-100Insulin Degludec | 105 | $60,959 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 14 | $46,539 |
| ProliaDenosumab | 17 | $29,178 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 126 | $20,372 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $19,638 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 12 | $19,492 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $856 | $666,038417 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $643 | $458,077322 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $444 | $440,173349 claims |
| AstraZenecaFarxiga | $186 | $93,53793 claims |
| AmgenProlia | $416 | $29,17817 claims |
| AbbVieSynthroid, Armour Thyroid | $15 | $6,32365 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $53 | $5,405546 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Jacksonville
- David SuttonJacksonville$3.1M
- Mae Sheikh AliJacksonville$2.9M
- James MageeJacksonville$2.7M
- Senan SultanJacksonville$2.5M
- J EvansJacksonville$1.7M
- Wasim DeebJacksonville$1.5M
- Ricardo SilvaJacksonville$867K
- Anil ShresthaJacksonville$602K
- Joe ChehadeJacksonville$542K
- Firas WardaJacksonville$440K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.